ImmunityBio (IBRX) is higher as investors continue to reprice the stock around two fresh developments from April 2026: (1) a sharp step-up in early 2026 ANKTIVA commercial traction, and (2) steps to address FDA promotional compliance concerns that weighed on sentiment in late March. The most tangible catalyst has been the company’s preliminary Q1 2026 net product revenue of approximately $44.2 million—about 168% higher than Q1 2025—alongside an estimated $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026.

ImmunityBio’s April 2026 update highlighted record quarterly net product revenue, extending sequential growth since ANKTIVA’s commercial launch and reinforcing the view that physician adoption is expanding post-launch. The cash balance cited for March 31, 2026 matters because it reduces near-term funding anxiety for a commercial-stage biotech that is still building scale.

IBRX remains headline-sensitive after the FDA posted a March 13, 2026 warning letter focused on promotional communications for ANKTIVA. In early April 2026, ImmunityBio said it submitted a comprehensive response and outlined corrective measures, which investors have treated as a sign the situation may be containable versus escalating into broader commercial disruption.

Near-term, traders will focus on whether the preliminary revenue figure is confirmed when ImmunityBio files its quarterly financial statements, and whether ANKTIVA momentum remains intact into Q2. Investors are also monitoring any follow-on FDA correspondence tied to the March 2026 warning letter and ongoing legal headlines tied to the late-March drawdown.